mutations, in whom rituximab seems to possess tiny additional worth.59 Other genomic subgroups, which include sufferers with BIRC3gene in individuals relapsing following cure with the BCL2 antagonist venetoclax. 66 Resistance to those brokers is connected to these mutations in all-around 70% of cases, although they are usually subclonal and their c